|
|
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity |
| 5R01AI152251-03 |
|
NIAID |
2022 |
|
|
Role of miRNA Dysregulation on T Cell Differentiation and Function in MS |
| 5R01AI152435-03 |
|
NIAID |
2022 |
|
|
Design and development of HDAC11-specific chemical inhibitors for disease treatments |
| 5R01AI153110-02 |
|
NIAID |
2022 |
|
|
ThGM Cells in CNS Autoimmunity |
| 5R01AI155974-02 |
|
NIAID |
2022 |
|
|
Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis |
| 5R01AI156186-02 |
|
NIAID |
2022 |
|
|
Role of IL-7R in CNS autoimmunity |
| 5R01AI156384-02 |
|
NIAID |
2022 |
|
|
Mediator kinases as interferon antagonists in Down Syndrome |
| 5R01AI156739-03 |
|
NIAID |
2022 |
|
|
IL-37: a novel regulator of inflammation in CNS autoimmunity |
| 5R01AI160189-02 |
|
NIAID |
2022 |
|
|
TGF-b superfamily signaling in controlling Th17 cell function in autoimmune neuroinflammation |
| 5R01AI160774-02 |
|
NIAID |
2022 |
|
|
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis |
| 5R01AI161845-02 |
|
NIAID |
2022 |
